Sai Life Sciences Limited CC-Sep25.pdf · 2025-11-07
Hi, sir. Thanks for the opportunity. First question on the peptides. Just want to understand our capabilities. The discovery work that we're doing, is it for GLP -1 metabolism -related or for peptide drug conjugates? Because in one interview, Manish had spoken about peptide conjugates.
Got it. So would you then look at it molecule by molecule or would you want to go as a pitch as a platform play? So can you talk about what peptide length can we handle today? Are you using hybrid or continuous peptide synthesis? And how much of your peptide feedstock is imported? Like do we do the amino acid protection in-house or do we buy resin-loaded amino acids? If you can talk about your capabilities within peptides.